Clinical Trial

Impact of Anti-TNF, Vedolizumab and Tofacitinib on Aortic Stiffness, Carotid Intima-media Thickness and Cardiovascular Risk of Patients With Ulcerative Colitis

Study acronym: VASC-UC
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated May 29, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
An increased risk of cardiovascular (CV) diseases has been observed in patients with inflammatory bowel diseases (IBD). The impact of IBD drugs, such as anti-TNF, anti-integrins or anti-JAK, on the risk of CV events in IBD is remains unknown. Aortic pulse wave velocity (aPWV), a measure of aortic stiffness, and carotid intima media thickness (CIMT) are both predictors of cardiovascular events and are increased in patients with IBD. The investigators aimed to prospectively compare the CV risk, CIMT, arterial stiffness and biomarkers of endothelial dysfunction at baseline and after 3 and 12 months of anti-TNF, vedolizumab and tofacitinib.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2021-02-03; most recent amendment 2025-05-23.
Trial Details
NCT Number NCT04743518
Lead Sponsor Centre Hospitalier Universitaire, Amiens
Conditions Ulcerative Colitis
Enrollment 100 participants
Start Date 2021-02-02
Primary Completion 2025-12 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-05-29